Genetically Engineered Membrane‐Coated Nanoparticles as Versatile Platforms with Reduced Protein Corona for Targeted siRNA Delivery

Author:

Zhang Pengfei1,Zhao Lei1,Liu Heng2,Chen Hu34,Wu Yaming2,Wang Xiaoyong3,Liu Gang34ORCID,Zeng Yun2

Affiliation:

1. Institute of Molecular Immunology School of Laboratory Medicine and Biotechnology Southern Medical University Guangzhou 510000 China

2. Department of Pharmacy Xiamen Medical College Xiamen 361023 China

3. State Key Laboratory of Vaccines for Infectious Diseases Center for Molecular Imaging and Translational Medicine Xiang An Biomedicine Laboratory National Innovation Platform for Industry‐Education Integration in Vaccine Research School of Public Health Xiamen University Xiamen 361002 China

4. Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province (IKKEM) & Amoy Hopeful Biotechnology Co., Ltd. Xiamen 361027 China

Abstract

AbstractLow uptake efficiency in vivo as well as systemic toxicities of nucleic‐acid nanovehicles substantially retard the clinical translation of gene therapy. Targeted gene delivery to specific cell populations with antibody display techniques and membrane‐coated nanoparticle (NP) approaches may solve these problems. Here, a new class of targeted membrane‐camouflaged nanosystem is successfully constructed, which is made of polydopamine (PDA) nanoparticles coated with biosynthetic antibody‐displaying membranes from stem cells. In murine models of rheumatoid arthritis and colitis, the membrane‐camouflaged nanocarriers displayed anti‐CD64 antibodies in a ligand‐oriented way via the biosynthetic method and has reduced protein corona due to the coating of the negatively charged cell membrane, thereby achieving remarkable therapeutic efficacy through silencing the TNF expression selectively in CD64‐positive immune cell subsets. By expressing a wide variety of functional protein ligands on the cellular membranes that are further coated onto PDA nanoparticles, the membrane‐camouflaged nanosystems can also serve as a versatile theranostic platform that enables antibody‐targeted gene/siRNA delivery to the cells of interest in vivo, especially immune cells.

Funder

National Key Research and Development Program of China

China Postdoctoral Science Foundation

Fundamental Research Funds for the Central Universities

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmacology (medical),Biochemistry (medical),Genetics (clinical),Pharmaceutical Science,Pharmacology,Medicine (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3